Verismo Therapeutics, a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, announced an expansion of its partnership with Penn to include clinical cell manufacturing of Verismo's SynKIR-110 KIR-CAR T cell therapy by the Clinical Cell and Vaccine Production Facility (CVPF) at Penn's Perelman School of Medicine for clinical testing and potential use in a Phase I clinical trial.
CVPF is a cellular manufacturing facility with the capability to manufacture cellular therapy products for Phase I clinical trials, enabling the CVPF to help translate novel cellular therapies from bench to bedside. Verismo Therapeutics and CVFP are working together to translate the SynKIR-110 KIR-CAR T cell therapy from the lab to patients in a Phase I clinical trial.
"We are very excited to partner with the CVPF at Penn to make SynKIR-110 for a first-in-human clinical trial," said Dr. Bryan Kim, DMD, CEO at Verismo. "CVPF has a long history of producing cutting-edge cell therapies including the first FDA-approved genetically-engineered cell product as well as the first use of CRISPR-edited cells used in human clinical trials. Together, we will be well-positioned to manufacture SynKIR-110 for Phase I clinical testing."
The manufacturing partnership between Verismo and CVPF seeks to advance the promise of creating new treatment options for human diseases. The combination of CVPF's experience in cell production and cutting-edge cell therapy products being advanced by Verismo drives an aligned goal towards translating and manufacturing the next generation of advanced therapies to improve patient lives.
"Penn has always been a leader in innovating new cellular therapies that have the potential to have an immense impact on patient clinical care," said Dr. Gabriela Plesa, MD, PhD, CACT Deputy Director. "We look forward to working together with Verismo in hopes of bringing this new treatment option to patients."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!